主页 > 医学讨论 >
【medical-news】波生坦与Treprostinil治疗肺动脉高压
NEW YORK (Reuters Health) Aug 12 - In certain patients with moderate-to-severe pulmonary artery hypertension (PAH), the addition of oral bosentan to subcutaneous treprostinil-based therapy can produce further clinical improvement, investigators report in the July issue of Chest.
Dr. Raymond L. Benza and colleagues at the University of Alabama at Birmingham retrospectively studied 38 patients who were being treated with the long-acting prostacyclin analogue, treprostinil, and were followed for a mean of about 33 months.
Bosentan was added to the regimen of 12 patients who had remained in NYHA functional class III after a year of therapy and another 7 who had experienced intolerable treprostinil-related side effects that limited therapy.
Overall, mean pulmonary artery pressure decreased from 59.7 to 50.5 mm Hg, a significant difference. There was significant and sustained improvement in 6-minute walk distance and Borg dyspnea score.
The 19 patients who received bosentan showed additional significant improvements over baseline in these parameters.
At the outset of the study, 5% of patients were in NYHA functional class II or lower; by the last follow-up, this proportion had risen to 58%.
Dr. Benza and colleagues note that definitive conclusions cannot be drawn since this was a small, uncontrolled study. However, they conclude, the results suggest that adding bosentan to treprostinil "is safe, and may be associated with improvements in functional class, exercise capacity, and hemodynamics."
Chest 2008;134:139-145.
波生坦与Treprostinil治疗肺动脉高压产生协同效应
纽约(路透健康通讯社)8.12 –研究人员在第7期Chest杂志报道，部分中重度动脉高压 (PAH)病人, the addition of 口服波生坦与皮下 treprostinil为基础的治疗可产生更好的临床效果
伯明翰阿拉巴马大学Dr. Raymond L. Benza及同事回顾性调查了38个使用长效前列环素类似物 treprostinil的病人并中位随访33月.
选择12位（treprostinil）治疗一年后NYHA功能级别仍为 III 级及不能耐受treprostinil副反应的另7位患者在食物疗法基础上服用波生坦.
总体上, 肺动脉平均压从59.7 mm Hg下降至 50.5 mm Hg, 差别明显；6分钟步行距离和Borg呼吸困难评分改善显著且持续.
19位接受波生坦的病人其他基线参数也显著改善.
研究开始时, 5%病人NYHA功能级别为 II 级或更低; 至随访结束, 比例上升至58%.
Dr. Benza和同事指出，由于本研究病例少、没有设置严格对照，最后结论为时尚早；然而，作者认为，结果提示波生坦与treprostinil联合 "安全并且改善功能级别、运动能力和血液动力学."
Chest 2008;134:139-145.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-11-24 05:11
医学,生命科学网